Beilai Bio
Advancing the future of healthcare with stem cell therapeutics, converting medical waste into powerful solutions for high unmet medical needs.
Advancing the future of healthcare with stem cell therapeutics, converting medical waste into powerful solutions for high unmet medical needs.
Beilai Bio is a clinical-stage biopharmaceutical company founded in 2015 that is at the forefront of advancing the future of healthcare with its focus on stem cell therapeutics. The company's slogan "Advancing the future of healthcare with stem cell therapeutics, converting medical waste into powerful solutions for high unmet medical needs" encapsulates its mission to address significant unmet medical needs. Beilai Bio concentrates on developing stem cell therapies for a wide range of diseases, leveraging its advanced technology platforms to produce clinical-grade "off-the-shelf" Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) derived from an unlimited supply of cord tissues, typically considered as medical waste.
The company recently secured a CNY300.00M Series B investment on 15 April 2022, demonstrating significant confidence from investors in its innovative approach. Notable investors in this round include DT Capital Partners, SDIC Ventures, Huajin Capital, and Nanjing Jiangbei New Area Industrial Investment Group. Beilai Bio operates in the biotechnology industry, positioning itself in a rapidly evolving and impactful sector.
Overall, Beilai Bio's innovative technology, focus on addressing unmet medical needs, and recent substantial investment signify its potential to make a lasting impact in the healthcare and biopharmaceutical landscape.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | CNY300.00M | 4 |
|
15 Apr 2022 |
No recent news or press coverage available for Beilai Bio.
We care about your data, and we'd love to use cookies make your experience better.
